{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:54Z","timestamp":1786984374533,"version":"build-2736575974"},"reference-count":114,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RU2690 PruSEARCH HO2092\/7-1"],"award-info":[{"award-number":["RU2690 PruSEARCH HO2092\/7-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RA1026\/3-1"],"award-info":[{"award-number":["RA1026\/3-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["HO2092\/7-2"],"award-info":[{"award-number":["HO2092\/7-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RA1026\/3-2"],"award-info":[{"award-number":["RA1026\/3-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.anai.2025.11.007","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:29:41Z","timestamp":1763630981000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interleukin-31 targeting and other novel drugs in itch"],"prefix":"10.1016","volume":"136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3184-8376","authenticated-orcid":false,"given":"Peter","family":"Olah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Raap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Homey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2025.11.007_bib0001","doi-asserted-by":"crossref","unstructured":"St\u00e4nder S, Schmelz M, Lerner E, Murota H, Nattkemper L, Reich A, et al. A multidisciplinary Delphi consensus on the modern definition of pruritus: sensation and disease [e-pub ahead of print]. J Eur Acad Dermatol Venereol. https:\/\/doi.org\/10.1111\/jdv.20851, accessed September 2, 2025.","DOI":"10.1111\/jdv.20851"},{"issue":"213","key":"10.1016\/j.anai.2025.11.007_bib0002","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00015555-0369","article-title":"Pruritus: a review","author":"Weisshaar","year":"2003","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0003","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-3164.2010.00945.x","article-title":"Pruritus: an overview of current concepts","volume":"22","author":"Metz","year":"2011","journal-title":"Vet Dermatol"},{"issue":"9358","key":"10.1016\/j.anai.2025.11.007_bib0004","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S0140-6736(03)12570-6","article-title":"Itch","volume":"361","author":"Yosipovitch","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0005","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2340\/00015555-0305","article-title":"Clinical classification of itch: a position paper of the International Forum for the Study of Itch","volume":"87","author":"St\u00e4nder","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.anai.2025.11.007_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000446009","article-title":"Classification of itch","volume":"50","author":"St\u00e4nder","year":"2016","journal-title":"Curr Probl Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0007","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2340\/00015555-1620","article-title":"Pruritus assessment in clinical trials: consensus recommendations from the International Forum for the Study of Itch (IFSI) special interest group scoring itch in clinical trials","volume":"93","author":"St\u00e4nder","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0008","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/bjd\/ljae260","article-title":"International study on prevalence of itch: examining the role of itch as a major global public health problem","volume":"191","author":"Yosipovitch","year":"2024","journal-title":"Br J Dermatol"},{"issue":"24","key":"10.1016\/j.anai.2025.11.007_bib0009","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.2024.4899","article-title":"Chronic pruritus: a review","volume":"331","author":"Butler","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0010","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5826\/dpc.0902a03","article-title":"The itch-scratch cycle: a review of the mechanisms","volume":"9","author":"Rinaldi","year":"2019","journal-title":"Dermatol Pract Concept"},{"issue":"6733","key":"10.1016\/j.anai.2025.11.007_bib0011","doi-asserted-by":"crossref","first-page":"eadn9390","DOI":"10.1126\/science.adn9390","article-title":"Scratching promotes allergic inflammation and host defense via neurogenic mast cell activation","volume":"387","author":"Liu","year":"2025","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.abd.2024.09.006","article-title":"Pruritus in atopic dermatitis: a cross-sectional study of adult patients from a tertiary university hospital in S\u00e3o Paulo, Brazil","volume":"100","author":"Soares","year":"2025","journal-title":"An Bras Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0013","doi-asserted-by":"crossref","first-page":"5538","DOI":"10.5826\/dpc.1503a5538","article-title":"Patient burden and impact of moderate-to-severe atopic dermatitis in the Spanish healthcare system: the APOLO cross-sectional study","volume":"15","author":"De La Cueva Dobao","year":"2025","journal-title":"Dermatol Pract Concept"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0014","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2340\/00015555-2774","article-title":"Chronic prurigo of nodular type: a review","volume":"98","author":"Zeidler","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ejp.767","article-title":"The pathogenesis of Prurigo nodularis\u2013\u2018Super-Itch\u2019 in exploration","volume":"20","author":"Zeidler","year":"2016","journal-title":"Eur J Pain"},{"issue":"20","key":"10.1016\/j.anai.2025.11.007_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012390","article-title":"Chronic nodular prurigo: an update on the pathogenesis and treatment","volume":"23","author":"Wong","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0017","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jid.2024.06.1276","article-title":"Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation","volume":"145","author":"Kwatra","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2025.11.007_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1301817","article-title":"Molecular mechanisms of pruritus in prurigo nodularis","volume":"14","author":"Shao","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0019","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: new insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0020","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.jaad.2016.07.016","article-title":"Research letter: impact of pruritus on quality of life-a systematic review","volume":"75","author":"Kantor","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0021","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3778","article-title":"Impact of itch on sleep disturbance in patients with prurigo nodularis","volume":"101","author":"Gwillim","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0022","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1038\/s41598-024-58013-x","article-title":"Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in type 2 inflammation","volume":"14","author":"Cornman","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jaci.2025.02.029","article-title":"Endotypes of atopic dermatitis","volume":"156","author":"Fyhrquist","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0024","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: from mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0025","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1038\/s41467-020-16859-5","article-title":"Central circuit mechanisms of itch","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"issue":"7154","key":"10.1016\/j.anai.2025.11.007_bib0026","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/nature06029","article-title":"A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord","volume":"448","author":"Sun","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.anai.2025.11.007_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fncir.2022.805831","article-title":"The spino-parabrachial pathway for itch","volume":"16","author":"Piyush Shah","year":"2022","journal-title":"Front Neural Circuits"},{"key":"10.1016\/j.anai.2025.11.007_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2023.1272230","article-title":"Itch: from the skin to the brain - peripheral and central neural sensitization in chronic itch","volume":"16","author":"Mahmoud","year":"2023","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.anai.2025.11.007_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.643006","article-title":"How do neurons signal itch?","volume":"8","author":"Schmelz","year":"2021","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaci.2023.05.004","article-title":"Basic mechanisms of itch","volume":"152","author":"Misery","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2025.11.007_bib0031","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.tins.2010.09.002","article-title":"The multiple pathways for itch and their interactions with pain","volume":"33","author":"Davidson","year":"2010","journal-title":"Trends Neurosci"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0032","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2133.1976.tb04383.x","article-title":"Prostaglandins and pruritus","volume":"94","author":"Lovell","year":"1976","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mjd.2002.120462","article-title":"Prostaglandin E2 induces vasodilation and pruritus, but no protein extravasation in atopic dermatitis and controls","volume":"47","author":"Neisius","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.anai.2025.11.007_bib0034","doi-asserted-by":"crossref","unstructured":"Yanes DA, Mosser-Goldfarb JL. Emerging therapies for atopic dermatitis: the prostaglandin\/leukotriene pathway. J Am Acad Dermatol. 2018;78(3)(suppl 1):S71-S75.","DOI":"10.1016\/j.jaad.2017.12.021"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.13193","article-title":"Exploring the roles of prostanoids, leukotriens, and dietary fatty acids in cutaneous inflammatory diseases: insights from pharmacological and genetic approaches","volume":"317","author":"Honda","year":"2023","journal-title":"Immunol Rev"},{"issue":"11","key":"10.1016\/j.anai.2025.11.007_bib0036","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/j.1600-0625.2011.01346.x","article-title":"Involvement of leukotriene B4 in spontaneous itch-related behaviour in NC mice with atopic dermatitis-like skin lesions","volume":"20","author":"Andoh","year":"2011","journal-title":"Exp Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0037","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41467-023-36014-0","article-title":"Cross-species transcriptomic atlas of dorsal root ganglia reveals species-specific programs for sensory function","volume":"14","author":"Jung","year":"2023","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.anai.2025.11.007_bib0038","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1097\/j.pain.0000000000001973","article-title":"Quantitative differences in neuronal subpopulations between mouse and human dorsal root ganglia demonstrated with RNAscope in situ hybridization","volume":"161","author":"Shiers","year":"2020","journal-title":"Pain"},{"issue":"25","key":"10.1016\/j.anai.2025.11.007_bib0039","doi-asserted-by":"crossref","first-page":"eadj9173","DOI":"10.1126\/sciadv.adj9173","article-title":"Harmonized cross-species cell atlases of trigeminal and dorsal root ganglia","volume":"10","author":"Bhuiyan","year":"2024","journal-title":"Sci Adv"},{"issue":"8","key":"10.1016\/j.anai.2025.11.007_bib0040","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.tins.2023.05.005","article-title":"Somatosensory neuron types and their neural networks as revealed via single-cell transcriptomics","volume":"46","author":"Wang","year":"2023","journal-title":"Trends Neurosci"},{"key":"10.1016\/j.anai.2025.11.007_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2023.1162049","article-title":"Single-cell transcriptomic profiling of dorsal root ganglion: an overview","volume":"17","author":"Xie","year":"2023","journal-title":"Front Neuroanat"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0042","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0043","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2020.06.023","article-title":"The cytokine TGF-\u03b2 induces interleukin-31 expression from dermal dendritic cells to activate sensory neurons and stimulate wound itching","volume":"53","author":"Xu","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0044","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3390\/jcm12062091","article-title":"Pruritogenic mediators and new antipruritic drugs in atopic dermatitis","volume":"12","author":"Koumaki","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0045","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jaci.2025.05.011","article-title":"Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch","volume":"156","author":"Jha","year":"2025","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0046","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jid.2019.05.029","article-title":"Peripheral sensitization and loss of descending inhibition is a hallmark of chronic pruritus","volume":"140","author":"Pogatzki-Zahn","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.anai.2025.11.007_bib0047","article-title":"Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues","volume":"8","author":"Nemmer","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0048","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cea.12875","article-title":"Human basophils are a source of - and are differentially activated by - il-31","volume":"47","author":"Raap","year":"2017","journal-title":"Clin Exp Allergy"},{"issue":"7","key":"10.1016\/j.anai.2025.11.007_bib0049","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/jid.2015.106","article-title":"IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31","volume":"135","author":"Kunsleben","year":"2015","journal-title":"J Invest Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2025.11.007_bib0050","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.4049\/jimmunol.0900712","article-title":"Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells","volume":"184","author":"Niyonsaba","year":"2010","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0051","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaci.2022.11.009","article-title":"IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin","volume":"151","author":"Hashimoto","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0052","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3390\/pharmaceutics15020577","article-title":"Blockage of the IL-31 pathway as a potential target therapy for atopic dermatitis","volume":"15","author":"Orfali","year":"2023","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0053","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0054","first-page":"1","article-title":"Use of nemolizumab in the treatment of prurigo nodularis and atopic dermatitis","volume":"30","author":"Taha","year":"2025","journal-title":"Skin Therapy Lett"},{"issue":"12","key":"10.1016\/j.anai.2025.11.007_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113433","article-title":"Sensory neuronal STAT3 is critical for IL-31 receptor expression and inflammatory itch","volume":"42","author":"Takahashi","year":"2023","journal-title":"Cell Rep"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0056","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaci.2018.03.018","article-title":"Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study","volume":"142","author":"Kabashima","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0057","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2019.08.013","article-title":"Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus","volume":"145","author":"Silverberg","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0058","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s13555-023-00901-7","article-title":"Nemolizumab improves patient-reported symptoms of atopic dermatitis with pruritus: post hoc analysis of a Japanese Phase III randomized controlled trial","volume":"13","author":"Kabashima","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0059","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2024.4796","article-title":"Efficacy and safety of nemolizumab in patients with moderate to severe prurigo nodularis: the OLYMPIA 1 randomized clinical Phase 3 trial","volume":"161","author":"St\u00e4nder","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0060","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/bjd\/ljae131","article-title":"Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II\/III clinical study in patients aged \u2265 13 years","volume":"191","author":"Yokozeki","year":"2024","journal-title":"Br J Dermatol"},{"issue":"10451","key":"10.1016\/j.anai.2025.11.007_bib0061","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.anai.2025.11.007_bib0062","article-title":"Safety and efficacy of nemolizumab for atopic dermatitis with pruritus: a systematic review and meta-regression analysis of randomized controlled trials","volume":"13","author":"Liang","year":"2022","journal-title":"Front Immunol"},{"issue":"17","key":"10.1016\/j.anai.2025.11.007_bib0063","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1056\/NEJMoa2301333","article-title":"Phase 3 trial of nemolizumab in patients with prurigo nodularis","volume":"389","author":"Kwatra","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0064","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/bjd\/ljad268","article-title":"Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study","volume":"190","author":"Igarashi","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0065","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/bjd\/ljaf045","article-title":"Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged \u2265 13 years: efficacy and safety data from a phase II\/III study","volume":"193","author":"Yokozeki","year":"2025","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2025.11.007_bib0066","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13899","article-title":"Dupilumab: mechanism of action, clinical, and translational science","volume":"17","author":"McCann","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0067","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc\u2019h","year":"2020","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0068","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jaad.2020.02.060","article-title":"Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS","volume":"82","author":"Silverberg","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0069","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.anai.2025.11.007_bib0070","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/jdv.18221","article-title":"Efficacy of dupilumab in chronic prurigo and chronic idiopathic pruritus: a systematic review of current evidence and analysis of response predictors","volume":"36","author":"Gael","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0071","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/ph17010117","article-title":"Assessment of patient-reported outcomes at 48 months of treatment with dupilumab for severe atopic dermatitis: a single-center real-life experience with 126 patients","volume":"17","author":"Barei","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0072","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2019.07.074","article-title":"Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study","volume":"82","author":"Deleuran","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0073","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0074","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1159\/000531708","article-title":"Dupilumab for chronic prurigo: case series on effectiveness, safety, and quality of life","volume":"239","author":"Richter","year":"2023","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.anai.2025.11.007_bib0075","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1111\/all.15811","article-title":"Tralokinumab therapy for moderate-to-severe atopic dermatitis: clinical outcomes with targeted IL-13 inhibition","volume":"78","author":"Simpson","year":"2023","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0076","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/pharmaceutics15020568","article-title":"Targeting interleukin 13 for the treatment of atopic dermatitis","volume":"15","author":"Lytvyn","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0077","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0078","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0079","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40257-023-00806-3","article-title":"Tralokinumab efficacy over 1 year in adults with moderate-to-severe atopic dermatitis: pooled data from two Phase III trials","volume":"24","author":"Simpson","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0080","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jamadermatol.2023.0627","article-title":"Efficacy and safety of tralokinumab in adolescents with moderate to severe atopic dermatitis: the Phase 3 ECZTRA 6 randomized clinical trial","volume":"159","author":"Paller","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0081","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1093\/bjd\/ljae439","article-title":"Predicting success with reduced dosing frequency of tralokinumab in patients with moderate-to-severe atopic dermatitis","volume":"192","author":"Weidinger","year":"2025","journal-title":"Br J Dermatol"},{"issue":"S 1","key":"10.1016\/j.anai.2025.11.007_bib0082","first-page":"S77","article-title":"Efficacy and safety of tralokinumab in real life: possible predictive rapid response factors","volume":"35","author":"Potestio","year":"2024","journal-title":"Dermatitis"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0083","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjd.21867","article-title":"Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials","volume":"187","author":"Simpson","year":"2022","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2025.11.007_bib0084","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1007\/s13555-025-01446-7","article-title":"Real-world clinical experience of tralokinumab in a tertiary centre: an alternative for patients with conjunctivitis on dupilumab?","volume":"15","author":"Sebastian","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.anai.2025.11.007_bib0085","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2147\/CCID.S295672","article-title":"Managing atopic dermatitis with lebrikizumab - the evidence to date","volume":"15","author":"Labib","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0086","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40257-023-00793-5","article-title":"Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis","volume":"24","author":"Bernardo","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0087","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0088","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/bjd\/ljad435","article-title":"Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials","volume":"190","author":"Yosipovitch","year":"2024","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2025.11.007_bib0089","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12325-024-02974-y","article-title":"Improvement across dimensions of disease with lebrikizumab use in atopic dermatitis: two Phase 3, randomized, double-blind, placebo-controlled monotherapy trials (ADvocate1 and ADvocate2)","volume":"42","author":"Simpson","year":"2025","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0090","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-023-00792-6","article-title":"Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: an integrated analysis of eight clinical trials","volume":"24","author":"Stein Gold","year":"2023","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2025.11.007_bib0091","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s13555-025-01452-9","article-title":"Two-year efficacy and safety of lebrikizumab in patients with moderate-to-severe atopic dermatitis: a long-term extension (ADjoin)","volume":"15","author":"Guttman-Yassky","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.anai.2025.11.007_bib0092","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.5346","article-title":"Itch and Janus kinase inhibitors","volume":"103","author":"Han","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.anai.2025.11.007_bib0093","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: a network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0094","article-title":"Janus kinase inhibitors for the treatment of atopic dermatitis: focus on abrocitinib, baricitinib, and upadacitinib","volume":"11","author":"Nogueira","year":"2021","journal-title":"Dermatol Pract Concept"},{"issue":"5","key":"10.1016\/j.anai.2025.11.007_bib0095","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","article-title":"Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the Phase II and Phase III clinical trial program","volume":"22","author":"Simpson","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"10290","key":"10.1016\/j.anai.2025.11.007_bib0096","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0097","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2025.11.007_bib0098","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdcr.2021.06.028","article-title":"Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab","volume":"15","author":"Buttgereit","year":"2021","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0099","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s13555-021-00534-8","article-title":"Itch and sleep improvements with baricitinib in patients with atopic dermatitis: a post hoc analysis of 3 Phase 3 studies","volume":"11","author":"Buhl","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"12","key":"10.1016\/j.anai.2025.11.007_bib0100","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2025.11.007_bib0101","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0102","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jdermsci.2024.10.002","article-title":"Type 2 cytokine-JAK1 signaling is involved in the development of dry skin-induced mechanical alloknesis","volume":"117","author":"Toyosawa","year":"2025","journal-title":"J Dermatol Sci"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0103","doi-asserted-by":"crossref","first-page":"930","DOI":"10.4103\/idoj.idoj_449_24","article-title":"Abrocitinib: a comprehensive review of its efficacy and safety in dermatology","volume":"15","author":"Dogra","year":"2024","journal-title":"Indian Dermatol Online J"},{"issue":"7","key":"10.1016\/j.anai.2025.11.007_bib0104","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamadermatol.2024.1464","article-title":"Efficacy and safety of abrocitinib in prurigo nodularis and chronic pruritus of unknown origin: a nonrandomized controlled trial","volume":"160","author":"Kwatra","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.70287","article-title":"Effective treatment of prurigo nodularis with oral tofacitinib: a case report","volume":"13","author":"Mozafari","year":"2025","journal-title":"Clin Case Rep"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0106","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/medicina61061056","article-title":"Use of JAK inhibitors in Lichen Planus: an update","volume":"61","author":"Didona","year":"2025","journal-title":"Medicina"},{"issue":"8","key":"10.1016\/j.anai.2025.11.007_bib0107","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1080\/09546634.2022.2116926","article-title":"JAK inhibitors in lichen planus: a review of pathogenesis and treatments","volume":"33","author":"Motamed-Sanaye","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"12","key":"10.1016\/j.anai.2025.11.007_bib0108","first-page":"2244","article-title":"Examining the safety profile of Janus Kinase (JAK) inhibitors in the management of immune-mediated diseases: a comprehensive review","volume":"13","author":"Kraev","year":"2023","journal-title":"Life (Basel)"},{"issue":"10","key":"10.1016\/j.anai.2025.11.007_bib0109","doi-asserted-by":"crossref","first-page":"4128","DOI":"10.4103\/jfmpc.jfmpc_112_24","article-title":"JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: practical pearls for the primary care physician","volume":"13","author":"Beard","year":"2024","journal-title":"J Fam Med Prim Care"},{"issue":"3","key":"10.1016\/j.anai.2025.11.007_bib0110","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0111","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s11096-023-01569-x","article-title":"Topical Janus kinase inhibitors in atopic dermatitis: a safety network meta-analysis","volume":"45","author":"Alves","year":"2023","journal-title":"Int J Clin Pharm"},{"issue":"9","key":"10.1016\/j.anai.2025.11.007_bib0112","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of Upadacitinib vs Dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2025.11.007_bib0113","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3390\/medicina61040631","article-title":"New and emerging biologics and Jak inhibitors for the treatment of prurigo nodularis: a narrative review","volume":"61","author":"Bianco","year":"2025","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.anai.2025.11.007_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16704","article-title":"Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis","volume":"9","author":"Gao","year":"2023","journal-title":"Heliyon"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625013432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120625013432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T11:32:02Z","timestamp":1773919922000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120625013432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1081120625013432"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2025.11.007","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-31 targeting and other novel drugs in itch","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2025.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}